VERAXA Biotech (NASDAQ: VRXA) is broadening its reliance on human-relevant preclinical testing methods across its antibody-based cancer drug development programs, a strategic shift that could enhance the translatability of its research and reduce dependence on animal models. The company is implementing New Approach Methodologies (NAMs), including three-dimensional tumor spheroid models and patient-derived tumor models, to support its BiTAC® T-cell engagers, antibody-drug conjugates (ADCs), and bispecific antibody-drug conjugates (bispecific ADCs).
The announcement carries significant implications for both drug development and animal welfare. VERAXA reported that its lead BiTAC T-cell engager demonstrated selective and potent T-cell-mediated tumor-cell killing across 10 patient-derived non-small cell lung cancer models, while relevant controls showed minimal activity. Notably, the ex vivo study required approximately 10 mice, compared with an estimated 200 or more for comparable in vivo efficacy studies. This reduction underscores the potential of NAMs to not only improve clinical relevance but also to substantially decrease animal use and associated costs.
The findings support VERAXA’s dual-targeting approach, which is designed to direct immune activity toward cancer cells expressing two selected targets, and its broader strategy of using human-relevant models in preclinical research. By leveraging patient-derived models, VERAXA aims to generate data that more accurately predict human responses, potentially increasing the success rate of clinical trials and accelerating the path to market for its therapies.
For investors, the expansion of NAMs could translate into more efficient use of research and development budgets, as these methods may reduce the time and resources required for preclinical testing. The company’s focus on next-generation antibody-based therapeutics, including bispecific T cell engagers and bispecific ADCs, positions it in a competitive space where innovation in preclinical testing can be a key differentiator. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory, a world-renowned institution known for pioneering life science research and cutting-edge technology.
To view the full article, visit https://ibn.fm/jZrd2. For regular updates about VERAXA Biotech, visit https://investors.veraxa.com. The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA.
InvestorWire, a specialized communications platform focused on advanced wire-grade press release syndication, is one of 75+ brands within the Dynamic Brand Portfolio @ IBN. The platform provides access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries. It also offers article and editorial syndication to 5,000+ outlets, enhanced press release enhancement to ensure maximum impact, and social media distribution via IBN to millions of social media followers. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public.
